Haleon (HLN) Total Non-Current Liabilities (2021 - 2025)
Haleon (HLN) posted Total Non-Current Liabilities of $14.9 billion for Q4 2025, down 5.36% on a QoQ basis from $15.8 billion in Q4 2024, and down 5.36% year-over-year from $15.8 billion in Q4 2024.
Haleon (HLN) Total Non-Current Liabilities (2021 - 2025) Analysis & Trends
Haleon's Total Non-Current Liabilities history runs 5 years deep, the most recent figure standing at $14.9 billion for Q4 2025.
- Quarterly Total Non-Current Liabilities fell 5.36% year-over-year to $14.9 billion in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $14.9 billion (down 5.36% YoY) and the FY2025 annual result came in at $14.8 billion, down 5.81% from the prior year.
- Total Non-Current Liabilities was $14.9 billion for Q4 2025 at Haleon, down from $15.8 billion in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $16.4 billion in Q4 2022 and bottomed at -$17.4 billion in Q2 2022.
- A 5-year average of $2.6 billion and a median of $10.0 billion in 2021 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2022 — Total Non-Current Liabilities soared 226.04% — and 2025, when it fell 5.36%.
- Haleon's Total Non-Current Liabilities stood at $5.0 billion in 2021, then surged by 226.04% to $16.4 billion in 2022, then retreated by 4.03% to $15.7 billion in 2023, then increased by 0.09% to $15.8 billion in 2024, then decreased by 5.36% to $14.9 billion in 2025.
- Business Quant data shows HLN's Total Non-Current Liabilities at $14.9 billion in Q4 2025, $15.8 billion in Q4 2024, and -$14.0 billion in Q2 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 14.92 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 18.28 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 33.47 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 599.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 20.09 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 1.24 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 6.26 Bn |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn | 604.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 14.92 Bn |
| Dec 31, 2024 | 15.76 Bn |
| Jun 30, 2024 | -13.97 Bn |
| Dec 31, 2023 | 15.75 Bn |
| Jun 30, 2023 | -15.78 Bn |
| Dec 31, 2022 | 16.41 Bn |
| Jun 30, 2022 | -17.39 Bn |
| Dec 31, 2021 | 5.03 Bn |